Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

1.130 -0.180 (-13.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,006,961
Open 1.310
Bid (Size) 1.130 (400)
Ask (Size) 1.180 (4,000)
Prev. Close 1.310
Today's Range 1.120 - 1.310
52wk Range 0.9657 - 9.790
Shares Outstanding 5,726,750
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical... 
Via Newsfile

Performance

YTD
-40.5%
-40.5%
1 Month
-27.1%
-27.1%
3 Month
-46.7%
-46.7%
6 Month
-59.5%
-59.5%
1 Year
-58.6%
-58.6%

More News

Read More
News headline image
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Via Newsfile
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
Via Newsfile
News headline image
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
Via Newsfile
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
These stocks are the most active in today's session ↗
Via Chartmill
News headline image
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
Via Newsfile
News headline image
Why Is Phio Pharmaceuticals Stock Soaring Today? ↗
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Via Newsfile
News headline image
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
Via Newsfile
News headline image
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Via Newsfile
News headline image
Phio Posts Wider Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Via Newsfile
News headline image
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
Via Newsfile

Frequently Asked Questions

Is Phio Pharmaceuticals Corp. - Common Stock publicly traded?
Yes, Phio Pharmaceuticals Corp. - Common Stock is publicly traded.
What exchange does Phio Pharmaceuticals Corp. - Common Stock trade on?
Phio Pharmaceuticals Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phio Pharmaceuticals Corp. - Common Stock?
The ticker symbol for Phio Pharmaceuticals Corp. - Common Stock is PHIO on the Nasdaq Stock Market
What is the current price of Phio Pharmaceuticals Corp. - Common Stock?
The current price of Phio Pharmaceuticals Corp. - Common Stock is 1.130
When was Phio Pharmaceuticals Corp. - Common Stock last traded?
The last trade of Phio Pharmaceuticals Corp. - Common Stock was at 12/08/25 04:00 PM ET
What is the market capitalization of Phio Pharmaceuticals Corp. - Common Stock?
The market capitalization of Phio Pharmaceuticals Corp. - Common Stock is 6.47M
How many shares of Phio Pharmaceuticals Corp. - Common Stock are outstanding?
Phio Pharmaceuticals Corp. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.